Study to Evaluate PI3K and VPS34 Inhibitors for Combination Efficacy Across
Distinct Glioblastoma Subtypes
San Diego, CA — June 19, 2026 — Global Cancer Technology (GCT), a preclinical-stage biopharmaceutical company
developing novel oncology therapeutics, today announced a research collaboration with The University of New Mexico
(UNM). Under the collaboration, Tou Yia Vue, PhD, Associate Professor of Neurosciences and member of the UNM
Comprehensive Cancer Center at the UNM School of Medicine, will investigate GCT’s lead compounds—GCT-007, a PI3K
inhibitor with downstream autophagy blockade, and GCT-008, a VPS34 inhibitor—in established animal models of
glioblastoma (GBM). Dr. Vue’s laboratory has developed an immunocompetent glioblastoma mouse model that recapitulates
the molecular diversity, cellular heterogeneity, and invasive growth patterns observed in human disease. Published in Nature
Communications in 2024, the model provides a clinically relevant platform for evaluating emerging therapeutic strategies
across distinct glioblastoma subtypes. This collaboration expands GCT’s growing network of leading academic research
partners and represents another important step toward advancing GCT-007 into clinical trials.
Glioblastoma is one of the most aggressive and treatment-resistant forms of brain cancer, with a median survival of
approximately 15 months following standard-of-care therapy. GCT’s compounds, which target the PI3K signaling axis and
downstream autophagy pathways, represent a novel mechanistic approach to addressing tumor progression across multiple
disease subtypes.
The primary objective of Dr. Vue’s laboratory is to evaluate GCT-007 and GCT-008, both alone and in combination with
immune checkpoint inhibitors and other chemotherapeutic agents, across animal models representing distinct molecular
subtypes of glioblastoma. The goal is to identify synergistic treatment regimens capable of overcoming resistance
mechanisms.
“The PI3K signaling pathway plays a central role in glioblastoma progression and treatment resistance,” said Dr. Vue. “This
collaboration allows us to develop innovative strategies to rigorously evaluate whether targeting PI3K and autophagy with
GCT’s compounds can slow tumor growth in multiple subtypes of glioblastoma in the brain or our mouse models. The
combination arms of this study may also reveal important synergies with existing immunotherapy and chemotherapy
approaches.”
“We are very excited to partner with Dr. Vue and The University of New Mexico on this important program,” said John
Clark, Founder and Chief Executive Officer of Global Cancer Technology. “Glioblastoma remains one of the most difficult
cancers to treat. With GCT-007’s established blood-brain barrier penetration and immune-priming activity, along with our
GCT-008 VPS34 inhibitor, we believe these compounds have real potential in this setting. The expertise of Dr. Vue’s
laboratory in glioblastoma biology and translational research makes UNM an ideal partner for advancing this work. This
collaboration, together with our ongoing research at other leading institutions, strengthens the compelling preclinical
foundation supporting GCT’s planned Phase I clinical development.”
The study is expected to commence immediately, with initial data anticipated within the next 6 to 12 months. Findings from
the collaboration are expected to be presented at major scientific conferences and submitted for publication in peer-reviewed
journals. The results will help further define the therapeutic potential of GCT-007 and GCT-008, both as standalone therapies
and in combination with immunotherapy and chemotherapy approaches for glioblastoma.
About Global Cancer Technology
Global Cancer Technology is a preclinical-stage biopharmaceutical company focused on advancing therapies for aggressive
and treatment-resistant cancers. GCT’s intellectual property portfolio includes U.S. Patent No. 12,637,450, issued in May
2026, covering the chemistry of GCT-007, and a companion patent covering GCT-008. The company has generated validated
preclinical data through collaborations with Barrow Neurological Institute, The University of Texas MD Anderson Cancer
Center, Mayo Clinic, Brown University, Baylor College of Medicine, and the University of Colorado. GCT is currently
advancing IND-enabling activities and raising capital to support a planned Phase I clinical trial in glioblastoma.
Learn more at www.globalcancertechnology.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that may cause
actual results to differ materially from those expressed or implied by such statements. There can be no assurance that any
investigational product candidate will complete development, obtain regulatory approval, or achieve commercial success.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this
release.
